Squarepoint
RVMD icon

Squarepoint’s Revolution Medicines RVMD Stock Holding History

Squarepoint’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-120,769
Closed -$17.6M – 4903
2026
Q1 		$11.7M Buy
120,769
+97,134
+411% +$9.81M 0.01% 988
2025
Q4 		$1.88M Buy
23,635
+13,256
+128% +$869K ﹤0.01% 2108
2025
Q3 		$485K Sell
10,379
-328,374
-97% -$12.9M ﹤0.01% 3259
2025
Q2 		$12.5M Buy
338,753
+245,934
+265% +$9.45M 0.01% 962
2025
Q1 		$3.28M Buy
+92,819
New +$3.77M ﹤0.01% 1715
2023
Q4 		– Sell
-117,302
Closed -$3.25M – 4424
2023
Q3 		$3.25M Buy
117,302
+90,623
+340% +$2.69M 0.01% 1462
2023
Q2 		$714K Buy
+26,679
New +$655K ﹤0.01% 2409
2023
Q1 		– Sell
-19,271
Closed -$459K – 3742
2022
Q4 		$459K Buy
+19,271
New +$410K ﹤0.01% 2331
2021
Q3 		– Sell
-145,886
Closed -$4.63M – 3360
2021
Q2 		$4.63M Buy
+145,886
New +$5.09M 0.02% 759
2021
Q1 		– Sell
-14,094
Closed -$558K – 3543
2020
Q4 		$558K Buy
+14,094
New +$557K ﹤0.01% 1737

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Squarepoint's RVMD Position: Q2 2026 in Review

Squarepoint sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 120,769 shares — an estimated $17.6M sold.

Squarepoint first reported a position in RVMD in Q4 2020 and held it in 10 quarters. The position peaked at $12.5M in Q2 2025. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Squarepoint reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 120,769 Revolution Medicines shares in Q2 2026, an estimated $17.6M.
  • Squarepoint first reported a position in Revolution Medicines in Q4 2020 and held it in 10 quarters.
  • Squarepoint's Revolution Medicines position peaked at $12.5M in Q2 2025.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.